Cancer Genetics Research
New drugs are being identified for assessment in clinical trials that target specific genetic profiles in children with neuroblastoma.
Researchers are investigating how the genetic profiles of tumors from children with neuroblastoma are indicative of how aggressively they behave and are also working to identify potential avenues for targeted intervention.
CHD5, a gene located on the distal portion of the short arm of chromosome 1, may function as a tumor suppressor gene and contribute to the development of malignant neuroblastoma when deleted.
Identifying the underlying genetic causes of high-risk acute lymphocytic leukemia can provide clues to potential therapeutic targets.
Researchers at the Center for Childhood Cancer Research are working to generate a series of position papers intended to detail the recommended best practices for pediatric cancer surveillance.
Treating patients with Philadelphia chromosome-like acute lymphoblastic leukemia with a combination of chemotherapy and tyrosine kinase inhibitors may result in higher cure rates.
Identifying and understanding the dynamic rewiring of gene network is critical for understanding cancer pathogenesis and development of therapeutic interventions.
Researchers at the Center for Childhood Cancer Research, led by Kai Tan, PhD, are developing a general computational framework for identifying noncoding genetic mutations that confer cancer risk.
Researchers at the Center for Childhood Cancer Research, led by Kai Tan, PhD, are developing cutting-edge genomic and computational tools to profile and model the gene regulatory circuitry during HSC development.
Inhibition of the TRK tyrosine kinase family has shown enduring response in clinical trials and efforts are underway to assess newer TRK inhibitors.
Investigators are examining the use of injectable alpha-emitting radionuclide MABG, a potent form of radiotherapy that specifically targets neuroblastoma cells.
The use of NGS allows massive parallel deep sequencing to screen hundreds of genes for cancer-related mutations can provide important information at the time of diagnosis and throughout the clinical course of the disease.